- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Metasyn joins forces with Daiichi
Contrast developer Metasyn has signed a $12 million agreementwith Daiichi Radioisotope Laboratories of Tokyo for Japanese developmentand marketing of MS-325, Metasyn's vascular MRI contrast agent.Under the agreement, Metasyn will receive $12 million in
Contrast developer Metasyn has signed a $12 million agreement
with Daiichi Radioisotope Laboratories of Tokyo for Japanese development
and marketing of MS-325, Metasyn's vascular MRI contrast agent.
Under the agreement, Metasyn will receive $12 million in license
fees, milestone payments, and an equity investment, in addition
to royalties on sales of the product. Daiichi will be responsible
for clinical development, registration, and commercialization
of MS-325 in Japan. Metasyn, of Cambridge, MA, will manufacture
MS-325 for Daiichi and will retain rights to the product outside
Japan. Metasyn expects to begin clinical trials of the agent in
the U.S. this year.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
